4.7 Review

Chlamydomonas reinhardtii chloroplasts as protein factories

期刊

CURRENT OPINION IN BIOTECHNOLOGY
卷 18, 期 2, 页码 126-133

出版社

CURRENT BIOLOGY LTD
DOI: 10.1016/j.copbio.2007.02.001

关键词

-

资金

  1. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059614] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054659] Funding Source: NIH RePORTER
  3. NIAID NIH HHS [AI059614] Funding Source: Medline
  4. NIGMS NIH HHS [R01 GM054659-07, R01 GM054659] Funding Source: Medline

向作者/读者索取更多资源

Protein-based therapeutics are the fastest growing sector of drug development, mainly because of the high sensitivity and specificity of these molecules. Their high specificity leads to few side effects and excellent success rates in drug development. However, the inherent complexity of these molecules restricts their synthesis to living cells, making recombinant proteins expensive to produce. In addition to therapeutic uses, recombinant proteins also have a variety of industrial applications and are important research reagents. Eukaryotic algae offer the potential to produce high yields of recombinant proteins more rapidly and at much lower cost than traditional cell culture. Additionally, transgenic algae can be grown in complete containment, reducing any risk of environmental contamination. This system might also be used for the oral delivery of therapeutic proteins, as green algae are edible and do not contain endotoxins or human viral or prion contaminants.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据